EGFR activity in HER-2 over-expressing metastatic breast cancer: Evidence for simultaneous phosphorylation of Her-2/neu and EGFR

Oncology Reports

Volumn 14, Issue 2, 2005, Pages 305-311

  Gschwantler Kaulich, Daphne ^a   Hudelist, Gernot ^b   Koestler, Wolfgang J ^a,d   Czerwenka, Klaus ^a   Mueller, Ruth ^a   Helmy, Samir ^a   Ruecklinger, Ernst ^c   Kubista, Ernst ^a,d   Singer, Christian F ^a,d  

^a MEDICAL UNIVERSITY OF VIENNA   (Austria)

^b LKH Villach ^*  (Austria)

^c Ruecklinger KEG   (Austria)

^d LUDWIG BOLTZMANN INSTITUTE FOR LUNG VASCULAR RESEARCH   (Austria)

Author keywords

Activated EGFR; Activated Her 2 neu; Breast cancer; EGFR; Her 2 neu

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR; EPIDERMAL GROWTH FACTOR RECEPTOR 2;

ADULT; AGED; ARTICLE; BLOOD; BREAST TUMOR; COMPARATIVE STUDY; FEMALE; HUMAN; IMMUNOHISTOCHEMISTRY; METABOLISM; METASTASIS; MIDDLE AGED; PATHOLOGY; PHOSPHORYLATION; PROGNOSIS;

ADULT; AGED; AGED, 80 AND OVER; BREAST NEOPLASMS; FEMALE; HUMANS; IMMUNOHISTOCHEMISTRY; MIDDLE AGED; NEOPLASM METASTASIS; PHOSPHORYLATION; PROGNOSIS; RECEPTOR, EPIDERMAL GROWTH FACTOR; RECEPTOR, ERBB-2;

EID: 24744440384     PISSN: 1021335X     EISSN: 17912431     Source Type: Journal    
DOI: 10.3892/or.14.2.305     Document Type: Article

References (38)

1. Vogel CL, Cobleigh MA, Tripathy D, Gutheil JC, Harris LN, Fehrenbacher L, Slamon DJ, Murphy M, Novotny WF, Burchmore M, Shak S, Stewart SJ and Press M: Efficacy and safety of trastuzumab as a single agent in first-line treatment of HER2-overexpressing metastatic breast cancer. J Clin Oncol 20: 719-726, 2002. (Pubitemid 34111379)
2. Tsutsui S, Kataoka A, Ohno S, Murakami S, Kinoshita J and Hachitanda Y: Prognostic and predictive value of epidermal growth factor receptor in recurrent breast cancer. Clin Cancer Res 8: 3454-3460, 2002. (Pubitemid 35340721)
3. Buzdar AU, Ibrahim NK, Francis D, Booser DJ, Thomas ES, Theriault RL, Pusztai L, Green MC, Arun BK, Giordano SH, Cristofanilli M, Frye DK, Smith TL, Hunt KK, Singletary SE, Sabin AA, Ewer MS, Buchholz TA, Berry D and Hortobagyi GN: Significantly higher pathologic complete remission rate after neoadjuvant therapy with trastuzumab, paclitaxel, and epirubicin chemotherapy: results of a randomized trial in human epidermal growth factor receptor 2-positive operable breast cancer. J Clin Oncol, early release, published online ahead of print Feb 28, 2005.
4. Slamon DJ, Leyland-Jones B, Shak S, Fuchs H, Paton V, Bajamonde A, Fleming T, Eiermann W, Wolter J, Pegram M, Baselga J and Norton L: Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N Engl J Med 344: 783-792, 2001. (Pubitemid 32222155)
5. Seshadri R, McLeay WR, Horsfall DJ and McCaul K: Prospective study of the prognostic significance of epidermal growth factor receptor in primary breast cancer. Int J Cancer 69: 23-27, 1996. (Pubitemid 26083266)
6. Schroeder W, Biesterfeld S, Zillessen S and Rath W: Epidermal growth factor receptor-immunohistochemical detection and clinical significance for treatment of primary breast cancer. Anticancer Res 17: 2799-2802, 1997. (Pubitemid 27352690)
7. Robertson KW, Reeves JR, Smith G, Keith WN, Ozanne BW, Cooke TG and Stanton PD: Quantitative estimation of epidermal growth factor receptor and c-erbB-2 in human breast cancer. Cancer Res 56: 3823-3830, 1996. (Pubitemid 26272035)
8. Suo Z, Risberg B, Kalsson MG, Willman K, Tierens A, Skovlund E and Nesland JM: EGFR family expression in breast carcinomas. c-erbB-2 and c-erbB-4 receptors have different effects on survival. J Pathol 196: 17-25, 2002.
9. Citri A, Skaria KB and Yarden Y: The deaf and the dumb: the biology of ErbB-2 and ErbB-3. Exp Cell Res 284: 54-65, 2003. (Pubitemid 36342255)
10. Roskoski R Jr: The ErbB/HER receptor protein-tyrosine kinases and cancer. Biochem Biophys Res Commun 319: 1-11, 2004.
11. Zabrecky JR, Lam T, McKenzie SJ and Carney W: The extra-cellular domain of p185/neu is released from the surface of human breast carcinoma cells, SK-BR-3. J Biol Chem 266: 1716-1720, 1991. (Pubitemid 21908361)
12. Ross JS, Fletcher JA, Bloom KJ, Linette GP, Stec J, Clark E, Ayers M, Symmans WF, Pusztai L and Hortobagyi GN: HER-2/neu testing in breast cancer. Am J Clin Pathol 120: 53-71, 2003.
13. Lane HA, Beuvink I, Motoyama AB, Daly JM, Neve RM and Hynes NE: ErbB2 potentiates breast tumor proliferation through modulation of p27(Kip1)-Cdk2 complex formation: receptor overexpression does not determine growth dependency. Mol Cell Biol 20: 3210-3223, 2000. (Pubitemid 30215033)
14. Olayioye MA, Neve RM, Lane HA and Hynes NE: The ErbB signaling network: receptor heterodimerization in development and cancer. EMBO J 19: 3159-3167, 2000. (Pubitemid 30428195)
15. Hudelist G, Singer CF, Manavi M, Pischinger K, Kubista E and Czerwenka K: Co-expression of ErbB-family members in human breast cancer: Her-2/neu is the preferred dimerization candidate in nodal-positive tumors. Breast Cancer Res Treat 80: 353-361, 2003. (Pubitemid 37046760)
16. Ullrich A and Schlessinger J: Signal transduction by receptors with tyrosine kinase activity. Cell 61: 203-212, 1990.
17. Tsutsui S, Ohno S, Murakami S, Kataoka A, Kinoshita J and Hachitanda Y: Prognostic value of the combination of epidermal growth factor receptor and c-erbB-2 in breast cancer. Surgery 133: 219-221, 2003. (Pubitemid 36407987)
18. Brandt-Rauf PW, Pincus MR and Carney WP: The c-erbB-2 protein in oncogenesis: molecular structure to molecular epidemiology. Crit Rev Oncog 5: 313-329, 1994.
19. Thor AD, Liu S, Edgerton S, Moore D, Kasowitz KM, Benz CC, Stern DF and Di Giovanna MP: Activation (tyrosine phosphorylation) of ErbB-2 (HER-2/neu): a study of incidence and correlation with outcome in breast cancer. J Clin Oncol 18: 3230-3239, 2000.
20. Sato K, Nagao T, Iwasaki T, Nishihira Y and Fukami Y: Src-dependent phosphorylation of the EGF receptor Tyr-845 mediates Stat-p21waf1 pathway in A431 cells. Genes Cells 8: 995-1003, 2003. (Pubitemid 38072275)
21. Simeonova PP, Wang S, Hulderman T and Luster MI: c-Src-dependent activation of the epidermal growth factor receptor and mitogen-activated protein kinase pathway by arsenic. Role in carcinogenesis. J Biol Chem 277: 2945-2950, 2002. (Pubitemid 34953329)
22. +-ATPase. J Biol Chem 275: 27832-27837, 2000.
23. Biscardi JS, Maa MC, Tice DA, Cox ME, Leu TH and Parsons SJ: c-Src-mediated phosphorylation of the epidermal growth factor receptor on Tyr845 and Tyrl 101 is associated with modulation of receptor function. J Biol Chem 274: 8335-8343, 1999.
24. Hudelist G, Kostler WJ, Atteins J, Czerwenka K, Muller R, Manavi M, Steger GG, Kubista E, Ziehnski CC and Singer CF: Her-2/neu-triggered intracellular tyrosine kinase activation: in vivo relevance of ligand-independent activation mechanisms and impact upon the efficacy of trastuzumab-based treatment. Br J Cancer 89: 983-991, 2003. (Pubitemid 37239199)
25. Graus-Porta D, Beerli RR, Daly JM and Hynes NE: ErbB-2, the preferred heterodimerization partner of all ErbB receptors, is a mediator of lateral signaling. EMBO J 16: 1647-1655, 1997. (Pubitemid 27151960)
26. Kostler WJ, Schwab B, Singer CF, Neumann R, Rucklinger E, Brodowicz T, Tomek S, Niedermayr M, Hejna M, Steger GG, Krainer M, Wiltschke C and Zielinski CC: Monitoring of serum Her-2/neu predicts response and progression-free survival to trastuzumab-based treatment in patients with metastatic breast cancer. Clin Cancer Res 10: 1618-1624, 2004. (Pubitemid 38435551)
27. Lipton A, Ali SM, Leitzel K, Demers L, Chinchilli V, Engle L, Harvey HA, Brady C, Nalin CM, Dugan M, Carney W and Allard J: Elevated serum Her-2/neu level predicts decreased response to hormone therapy in metastatic breast cancer. J Clin Oncol 20: 1467-1472, 2002. (Pubitemid 34260524)
28. Xu YH, Richert N, Ito S, Merlino GT and Pastan I: Characterization of epidermal growth factor receptor gene expression in malignant and normal human cell lines. Proc Natl Acad Sei USA 81: 7308-7312, 1984. (Pubitemid 15196172)
29. Pawlowski V, Revillion F, Hebbar M, Hornez L and Peyrat JP: Prognostic value of the type I growth factor receptors in a large series of human primary breast cancers quantified with a realtime reverse transcription-polymerase chain reaction assay. Clin Cancer Res 6: 4217-4225, 2000.
30. Palmer HJ, Tuzon CT and Paulson KE: Age-dependent decline in mitogenic stimulation of hepatocytes. Reduced association between Shc and the epidermal growth factor receptor is coupled to decreased activation of Raf and extracellular signal-regulated kinases. J Biol Chem 274: 11424-11430, 1999.
31. Wakeling AE, Nicholson RI and Gee JM: Prospects for combining hormonal and nonhormonal growth factor inhibition. Clin Cancer Res7:S4350-S4355,2001.
32. Newby JC, Johnston SR, Smith IE and Dowsett M: Expression of epidermal growth factor receptor and c-erbB2 during the development of tamoxifen resistance in human breast cancer. Clin Cancer Res 3: 1643-1651, 1997. (Pubitemid 27431575)
33. Knowlden JM, Hutcheson IR, Jones HE, Madden T, Gee JM, Harper ME, Barrow D, Wakeling AE and Nicholson RI: Elevated levels of epidermal growth factor receptor/c-erbB2 heterodimers mediate an autocrine growth regulatory pathway in tamoxifen-resistant MCF-7 cells. Endocrinology 144: 1032-1044, 2003. (Pubitemid 36262870)
34. Knoop AS, Bentzen SM, Nielsen MM, Rasmussen BB and Rose C: Value of epidermal growth factor receptor, HER2, p53, and steroid receptors in predicting the efficacy of tamoxifen in high-risk postmenopausal breast cancer patients. J Clin Oncol 19:3376-3384, 2001. (Pubitemid 32642190)
35. Gross ME, Shazer RL and Agus DB: Targeting the HER-kinase axis in cancer. Semin Oncol 31: 9-20, 2004. (Pubitemid 38543936)
36. Arteaga CL and Baselga J: Tyrosine kinase inhibitors: why does the current process of clinical development not apply to them? Cancer Cell 5: 525-531, 2004. (Pubitemid 38748914)
37. Lin NU and Winer EP: New targets for therapy in breast cancer: small molecule tyrosine kinase inhibitors. Breast Cancer Res 6: 204-210, 2004. (Pubitemid 39220375)
38. Arteaga CL, Moulder SL and Yakes FM: HER (erbB) tyrosine kinase inhibitors in the treatment of breast cancer. Semin Oncol 29:4-10, 2002. (Pubitemid 34816060)